(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on AI drug discovery, cloud platforms, precision medicine, big-data integration and virtual screening, driven by chronic disease demand and collaborative research.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Informatics Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Drug Discovery Informatics Market to Reach $7.74 Billion by 2030 as AI Adoption Accelerates
The global drug discovery informatics market is experiencing rapid growth as pharmaceutical and biotechnology organizations invest in advanced technologies to streamline research, improve predictive accuracy, and shorten drug development timelines. The market is projected to increase from $4.06 billion in 2025 to $4.63 billion in 2026, representing a compound annual growth rate (CAGR) of 14.1%.
Historical market growth has been supported by the increasing complexity of pharmaceutical research and development, expanding volumes of clinical trial data, broader use of computational chemistry tools, and continued advances in bioinformatics. Demand for faster and more efficient drug development processes has also encouraged organizations to adopt informatics platforms capable of integrating and analyzing large volumes of scientific and clinical information.
The drug discovery informatics market is forecast to reach $7.74 billion by 2030, expanding at a CAGR of 13.7%. Key growth factors include rising investment in artificial intelligence-enabled drug discovery, increasing adoption of precision medicine, expansion of collaborative research platforms, and greater emphasis on predictive modeling. Integration between informatics platforms and laboratory systems is also expected to improve data accessibility, research coordination, and decision-making throughout the drug development process.
Major drug discovery informatics market trends include the growing use of AI-driven research platforms, wider adoption of cloud-based informatics solutions, and deeper integration of big data analytics into pharmaceutical R&D. Virtual screening, molecular modeling, and advanced data management tools are becoming increasingly important as research organizations seek to identify promising therapeutic targets and optimize potential drug candidates more efficiently.
The rising prevalence of chronic diseases is a significant driver of market expansion. Drug discovery informatics systems enable researchers to investigate molecular changes associated with disease progression and treatment response, supporting the development of more targeted therapies. According to Diabetes UK, approximately 4.4 million people in the UK were living with a diabetes diagnosis in 2022-23. Around 8% had type 1 diabetes, while approximately 90% had type 2 diabetes. The growing burden of diabetes and other chronic conditions is increasing demand for innovative treatments and more productive discovery processes.
Technology providers are responding by introducing AI-powered life sciences solutions designed to improve the speed, accuracy, and efficiency of research. In May 2023, Google Cloud launched the Target and Lead Identification Suite and the Multiomics Suite. These offerings combine high-performance computing, generative AI, and advanced computational capabilities to support protein structure prediction, amino acid function analysis, genetic data analysis, precision medicine research, and in silico drug design.
Strategic acquisitions are also shaping the competitive environment. In May 2023, US-based clinical-stage biotechnology company Recursion Pharmaceuticals acquired Canada-based Cyclica Inc. for $40 million. The transaction combined Cyclica's digital chemistry expertise with Recursion's technology-enabled biological research capabilities, strengthening its position in data-driven drug discovery and informatics.
North America was the largest region in the drug discovery informatics market in 2025, supported by established pharmaceutical research infrastructure, strong technology adoption, and substantial investment in AI-enabled drug development. Asia-Pacific is expected to be the fastest-growing region during the forecast period. Regions covered include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.
Markets Covered:
1) By Service: In-House; Outsourced
2) By Application: Data Sequencing; Molecular Docking; Identification And Validation; Target Data Analysis
3) By End-User: Pharmaceutical Companies; Contract Research Organizations; Bio-Technology Companies
Subsegments:
1) By In-House: Data Management; Computational Chemistry; Bioinformatics; Cheminformatics; Predictive Modeling
2) By Outsourced: Contract Research Organizations (CROs); Specialized Informatics Providers; Data Analysis And Management Services
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment